183 related articles for article (PubMed ID: 37172969)
1. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
[TBL] [Abstract][Full Text] [Related]
2. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
3. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
4. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J
Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
6. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
[TBL] [Abstract][Full Text] [Related]
7. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S
Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949
[TBL] [Abstract][Full Text] [Related]
8. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
[TBL] [Abstract][Full Text] [Related]
9. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
10. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
14. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
15. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C
Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
[TBL] [Abstract][Full Text] [Related]
17. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
